<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00991796</url>
  </required_header>
  <id_info>
    <org_study_id>CS1008-A-E202</org_study_id>
    <nct_id>NCT00991796</nct_id>
  </id_info>
  <brief_title>CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Randomised, Double-Blinded, Placebo Controlled, Phase 2 Study of CS-1008 in Combination With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect on toxicity of the addition of CS 1008&#xD;
      to a platinum based chemotherapy regimen on the progression-free survival (PFS) in subjects&#xD;
      with stage IIIB wet or stage IV NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in progression-free survival (PFS) of patients treated with CS-1008 and paclitaxel/carboplatin versus placebo and paclitaxel/carboplatin</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in overall survival of patients treated with CS-1008 and paclitaxel/carboplatin versus placebo and paclitaxel/carboplatin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in objective response rate (ORR) of patients treated with CS-1008 and paclitaxel/carboplatin versus placebo and paclitaxel/carboplatin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in duration of response of patients treated with CS-1008 and paclitaxel/carboplatin versus placebo and paclitaxel/carboplatin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CS-1008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-1008 with carboplatin and paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with carboplatin and paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-1008</intervention_name>
    <description>CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg</description>
    <arm_group_label>CS-1008</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2</description>
    <arm_group_label>CS-1008</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2</description>
    <arm_group_label>CS-1008</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          -  Measurable disease as defined by RECIST criteria&#xD;
&#xD;
          -  Adequate organ and bone marrow function as evidenced by:&#xD;
&#xD;
               -  Hemoglobin &gt;= 9 g/dL;&#xD;
&#xD;
               -  ANC &gt;= 1.5 x 109/L;&#xD;
&#xD;
               -  Platelet count &gt;= 100 x 109/L;&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 mg/dL or creatinine clearance &gt; 60 mL/min;&#xD;
&#xD;
               -  AST, ALT, and alkaline phosphatase &lt;= 2.5 x upper limit of normal (ULN) if&#xD;
                  without liver metastasis and &lt;= 5.0 x ULN if liver metastasis;&#xD;
&#xD;
               -  Total bilirubin &lt;= 2.0 x ULN.&#xD;
&#xD;
          -  Men and women of childbearing potential must be willing to consent to using effective&#xD;
             double barrier contraception (eg, hormonal contraceptives, bilateral tubal ligation,&#xD;
             barrier with spermicidal, intrauterine device) while on treatment and for 3 months&#xD;
             thereafter.&#xD;
&#xD;
          -  All female subjects of childbearing potential must have a negative pregnancy test&#xD;
             (serum or urine) result &lt;= 72 hours before initiating study treatment.&#xD;
&#xD;
          -  Subjects must be fully informed about their illness and the investigational nature of&#xD;
             the study protocol (including foreseeable risks and possible side effects) and must&#xD;
             sign and date an IEC approved ICF before performance of any study specific procedures&#xD;
             or tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anticipation of need for a major surgical procedure or radiotherapy (RT) during the&#xD;
             study.&#xD;
&#xD;
          -  Prior treatment with chemotherapy for their disease.&#xD;
&#xD;
          -  History of any of the following conditions within 6 months before study enrolment:&#xD;
             myocardial infarction; New York Heart Association (NYHA) class II or higher&#xD;
             severe/unstable angina pectoris; coronary/peripheral artery bypass graft; NYHA class&#xD;
             III or IV congestive heart failure; cerebrovascular accident or transient ischemic&#xD;
             attack, pulmonary embolism, or other clinically significant thromboembolic event;&#xD;
             clinically significant pulmonary disease (eg, severe chronic obstructive pulmonary&#xD;
             disease or asthma); clinically significant pulmonary edema or anasarca.. See Section&#xD;
             17.2 for NYHA Classification.&#xD;
&#xD;
          -  Clinically significant pleural or pericardial effusions.&#xD;
&#xD;
          -  Grade 2 or higher current peripheral neuropathy (See Section 17.3; NCI CTCAE, Version&#xD;
             3.0).&#xD;
&#xD;
          -  Clinically active brain metastasis (ie, untreated, still requiring therapy with&#xD;
             steroids or RT, or with progression within 4 weeks after completion of RT); an&#xD;
             uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis.&#xD;
&#xD;
          -  History of malignancy other than NSCLC, unless there is the expectation that the&#xD;
             malignancy has been cured, and tumor specific treatment for the malignancy has not&#xD;
             been administered within the previous 5 years.&#xD;
&#xD;
          -  Clinically significant active infection that requires antibiotic therapy or Human&#xD;
             Immunodeficiency Virus (HIV) positive subjects receiving antiretroviral therapy.&#xD;
&#xD;
          -  Previous treatment with chemotherapy, CS 1008, other agonistic DR 5 or DR 4&#xD;
             antibodies, or with TRAIL.&#xD;
&#xD;
          -  Pregnant or breast feeding.&#xD;
&#xD;
          -  Known history of hypersensitivity reactions to any of the components of CS 1008,&#xD;
             carboplatin, or paclitaxel formulations.&#xD;
&#xD;
          -  Serious intercurrent medical or psychiatric illnesses or any other conditions that in&#xD;
             the opinion of the Investigator would impair the ability to give informed consent or&#xD;
             unacceptably reduce protocol compliance or safety of the study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asklepios Fachkliniken Munchen Gauting</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum fur Pneumologie und Thoraxchirurgie</name>
      <address>
        <city>Grobhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>October 7, 2009</study_first_submitted>
  <study_first_submitted_qc>October 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2009</study_first_posted>
  <last_update_submitted>September 7, 2012</last_update_submitted>
  <last_update_submitted_qc>September 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

